Back to News
Market Impact: 0.18
Scienture Expands REZENOPY Reach To Addiction Centers Under Distribution Deal
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Scienture Holdings subsidiary Scienture, LLC entered a distribution agreement to expand U.S. commercial access for REZENOPY Nasal Spray 10 mg across addiction treatment centers. The agreement supports broader product reach in a targeted treatment channel, though no financial terms, sales projections, or revenue impact were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
SCNX0.55
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- The AI ‘credit card’ is getting costlier as CoreWeave bond yield tops 16%
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal